Biogen to start shipping new Alzheimer's drug in two weeks

More than 900 clinics and hospitals around the US are ready to administer Biogen's recently-approved drug Aduhelm to Alzheimer's patients.


Significantly more infusion centers than expected are ready to give patients suffering from Alzheimer's disease Biogen's new medication Aduhelm, according to Fiercepharma.

900 infusion centers will be poised to administer this medication when Biogen starts shipping it in two weeks' time. In April, the estimated number of infusion centers was 600. In total, the US company estimates that 1,200 clinics around the US will be able to administer Aduhelm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs